Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

New Gene Therapies for Sickle Cell Face Big Access Hurdles Despite Promise

Published Oct 16, 2026
Share:
Summary:
  • The FDA cleared two gene therapies for severe sickle cell disease in 2023: Casgevy and Lyfgenia.
  • Studies found 88% to 94% of treated patients had no severe vaso-occlusive pain crises, but the process can take up to a year and uptake has been limited.
  • List prices run from 2.2 million to 3.1 million dollars, and access still varies by where patients live, provider availability, and access to specialized centers; 32 states plus D.C. and Puerto Rico are in CMS's 2024 model and coverage can differ by state.

A rare treatment with curative potential

For decades, many patients cycled through clinics, medications, and transfusions to manage a genetic blood disorder that can trim life expectancy by as much as 20 years. That changed course in 2023 when the FDA authorized Casgevy and Lyfgenia, the first gene therapies for severe sickle cell disease. "That opens up a whole world of individuals potentially being cured of sickle cell disease," said Dr. Edward Donnell Ivy, who is the chief medical officer at the Sickle Cell Disease Association of America.

The results so far are striking: in studies, 88% to 94% of patients reported complete freedom from severe vaso-occlusive pain crises. The promise is real, though actually getting treated remains a heavy lift.

How treatment works and who is eligible

Gene therapy collects a patient's blood-forming stem cells, edits them to boost healthy hemoglobin, then reinfuses those cells. Before that reinfusion, patients undergo conditioning that includes chemotherapy and transfusions, often with hospital stays that run for weeks. Start to finish, the process can extend to a year, and the conditioning step often causes permanent infertility or sterility.

Casgevy is authorized for patients as young as 2, while Lyfgenia is available beginning at age 12. Both target severe disease, including genotypes such as HbSS and HbS beta zero thalassemia. Likely candidates are those who had at least four pain crises or episodes of acute chest syndrome within the previous 24 months. Estimates suggest roughly 25% to 35% of the population with sickle cell disease meets current clinical criteria.

Slow uptake, high price tags, and uneven access

Despite the curative promise, uptake has lagged. Vertex Pharmaceuticals reported that by the end of 2025, 64 patients worldwide had undergone Casgevy infusions, and an additional 147 had finished their first cell collection. According to Genetix Biotherapeutics, 115 U.S. patients had received Lyfgenia since its 2023 approval, and by late 2025 another 216 had initiated cell collection.

When complex treatments raise questions about access and cost, sign up for the free Market Briefs newsletter to stay informed.

Prices are steep. A single course lists between 2.2 million and 3.1 million dollars, excluding hospitalizations, chemotherapy, and specialized care. To narrow coverage gaps, the Centers for Medicare and Medicaid Services launched the Cell and Gene Therapy Access Model in 2024, where CMS works with states and manufacturers on patient outcomes based pricing intended to lower costs for the therapy and related care.

Thirty two states, the District of Columbia, and Puerto Rico participate. Coverage still differs across jurisdictions. "Depending on the state that someone is in, some of the coverage may be more comprehensive than others," said Dr. Alexis Thompson, an attending hematologist at Children's Hospital of Philadelphia who also speaks on behalf of the American Society of Hematology.

She added, "The patients' priorities are actually a big part of really trying to figure out what the barriers to access are and how we overcome them."

The context investors need

Sickle cell disease affects about 100,000 people in the U.S., and more than 90% are non Hispanic Black or African American, per the CDC. The biology is punishing: rigid, crescent shaped red blood cells can block blood flow and limit oxygen delivery, driving complications from anemia and chronic fatigue to clots, infections, organ damage, stroke, and episodes of severe pain.

Progress took time. "In the past six or seven years, there's been an explosion" of new therapies, said Dr. Andrew Campbell of Children's National, but "from 1910 until about 2015, there was very little progress in disease modifying treatments for sickle cell disease." Funding lagged too. From 2008 to 2018, NIH support averaged 812 dollars per patient for sickle cell disease versus 2,807 dollars for cystic fibrosis, which affects about 40,000 people in the U.S. Hydroxyurea, approved in 1998, became a mainstay by roughly halving pain crises and reducing hospitalizations and transfusions.

Transplants offered a potential cure for some, but donor matches were a bottleneck. As Ivy noted, gene therapy changes that calculus because patients can serve as their own donor.

For portfolios, the setup is clear: a sizable eligible pool, premium pricing, and early throughput constrained by complex logistics and uneven coverage. If the 2024 CMS model gains traction and more specialized centers expand capacity, utilization could climb, and so could revenue for the companies behind these therapies.

Because policy and markets affect access to care, get clear daily context from the free Market Briefs newsletter.

Disclosure

Recent News

1 2 3 … 125

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 3, 2026
How to Budget Every Payday: 5 Moves So You Never Worry About Money
  • A median earner could make about $4.7 million over a career, yet most retire with closer to $13,000 in the bank because of a keeping problem, not an income problem.
  • Audit your money, save $2,000, pay off credit card debt, then automate a 75/15/10 split across three bank accounts.
  • Earn more only after your system is in place, then protect what you build with an accountant, attorneys, the right insurance, and an estate plan.
Read More
November 3, 2026
How to Invest in Stocks: 5 Things to Do Before You Invest Your First Dollar
  • Paying off credit card debt at around 22% interest beats the stock market's roughly 10% average, and even Warren Buffett's 19%.
  • Save $2,000 in a separate emergency fund, learn to research with AI, and decide whether you're a growth, income, or wealth preservation investor.
  • Write down a plan for buying during market crashes, which have happened 25 times in the last 100 years.
Read More
November 3, 2026
Best ETFs to Buy: 5 Three-ETF Portfolios for Every Investing Goal
  • An ETF is a basket of stocks, so one purchase spreads your money across many companies instead of riding on just one.
  • Jaspreet Singh laid out five portfolios of three ETFs each, built for kids, cash flow, growth, slow and steady growth, and protection from a weaker dollar.
  • Based on 10-year average returns, $500 a month could grow to between about $660,000 and $3.1 million over 30 years, though past returns never guarantee future ones.
Read More
November 3, 2026
Best Investments of a Generation: 5 Market Shifts Backed by Your Tax Dollars
  • Private companies are about to spend $1 trillion a year on AI, and the Trump administration is putting tax dollars behind the same industries.
  • The five shifts are AI and its supply chain, robotics, rare earths, energy, and defense.
  • Each comes with real risk, from an AI bubble to wars ending or a new Congress, so these are ideas to research, not sure things.
Read More
November 3, 2026
How to Get Ahead Financially: 10 Moves to Make While Everyone Else Falls Behind
  • Learning a high-income AI skill, or building AI tools for tradespeople, can raise your earning power in a tough job market.
  • Higher interest rates, the 2025 tax cuts, Trump accounts, and stacked cash back can put more money back in your pocket.
  • Following where government money is moving, keeping cash ready for market crashes, and investing in your own education can speed up your wealth.
Read More
November 3, 2026
National Debt at $40 Trillion: Why Inflation Is the Hidden Tax, and Who Profits From It
  • Time magazine asked President Trump how he'd tackle the $40 trillion national debt, and he suggested inflation could help pay it off, a cost that lands on everyday Americans.
  • From 1971 to 2025, cars, houses, and college outpaced both inflation and incomes, while the S&P 500 grew more than 33,000% with dividends reinvested.
  • The U.S. can default, inflate, or outgrow its debt, and history shows each path rewards different assets.
Read More
November 3, 2026
FOMC Meeting: Why the Fed Is Getting Nervous, and Why AI Stocks Feel It
  • At its latest meeting, the Fed held rates steady but warned it may raise them again, because inflation is running near 3.5% against a 2% target.
  • Oil prices, tariffs, AI's hunger for energy, and government spending are all pushing prices higher, and gold, silver, and bitcoin fell on the Fed's news.
  • Chinese AI stocks are down about 40% in a few months and Google fell more than 10% in a day, raising fears that higher rates could pop an AI bubble.
Read More
November 3, 2026
Midterm Elections: Where the Money Could Move if Republicans or Democrats Win
  • The U.S. government spent about $7.5 trillion last year, and the midterm elections could change which industries get more of that money.
  • A Republican win could favor manufacturing, fossil fuels, banks, and defense.
  • A Democratic win could favor healthcare, weight-loss drugs, clean energy, and infrastructure.
Read More
November 3, 2026
Brazil Stock Market Crash: Why Lula's Win Matters to U.S. Investors
  • Brazil's stock market fell more than 20% in a few days, and its currency dropped 8%, after Lula won a presidential election investors expected him to lose.
  • The shock reaches U.S. investors through coffee and beef prices, the BRICS push away from the dollar, and a market that had become an investor favorite.
  • The last time Lula first won, in 2002, Brazil's stock market fell more than 20% and then grew 12x by 2008, though nobody knows if that will repeat.
Read More
November 2, 2026
Credit Utilization: How Paying Down Cards Can Help Your Score
  • Credit utilization is your card balances divided by your credit limits, checked overall and card by card.
  • Lower is generally better, and Experian says the effect becomes more noticeable around 30%.
  • Paying down balances and keeping new charges off your cards are the main ways to lower it.
Read More
1 2 3 … 32
Share via
Copy link